P Svolos1, W E Reddick1, A Edwards1, A Sykes2, Y Li2, J O Glass1, Z Patay3. 1. From the Departments of Diagnostic Imaging (P.S., W.E.R., A.E., J.O.G., Z.P.). 2. Biostatistics (A.S., Y.L.), St. Jude Children's Research Hospital, Memphis, Tennessee. 3. From the Departments of Diagnostic Imaging (P.S., W.E.R., A.E., J.O.G., Z.P.) zoltan.patay@stjude.org.
Abstract
BACKGROUND AND PURPOSE: Assessing the response to treatment in infiltrative brain tumors by using lesion volume-based response criteria is challenging. We hypothesized that in such tumors, volume measurements alone may not accurately capture changes in actual tumor burden during treatment. We longitudinally evaluated volume changes in both normal-appearing supratentorial white matter and the brain stem lesions in patients treated for diffuse intrinsic pontine glioma to determine to what extent adjuvant systemic therapies may skew the accuracy of tumor response assessments based on volumetric analysis. MATERIALS AND METHODS: The anatomic MR imaging and diffusion tensor imaging data of 26 patients with diffuse intrinsic pontine glioma were retrospectively analyzed. Treatment included conformal radiation therapy in conjunction with vandetanib and dexamethasone. Volumetric and diffusion data were analyzed with time, and differences between time points were evaluated statistically. RESULTS: Normalized brain stem lesion volume decreased during combined treatment (slope = -0.222, P < .001) and increased shortly after completion of radiation therapy (slope = 0.422, P < .001). Supratentorial white matter volume steadily and significantly decreased with time (slope = -0.057, P < .001). CONCLUSIONS: Longitudinal changes in brain stem lesion volume are robust; less pronounced but measurable changes occur in the supratentorial white matter. Volume changes in nonirradiated supratentorial white matter during the disease course reflect the effects of systemic medication on the water homeostasis of normal parenchyma. Our data suggest that adjuvant nontumor-targeted therapies may have a more substantial effect on lesion volume changes than previously thought; hence, an apparent volume decrease in infiltrative tumors receiving combined therapies may lead to overestimation of the actual response and tumor control.
BACKGROUND AND PURPOSE: Assessing the response to treatment in infiltrative brain tumors by using lesion volume-based response criteria is challenging. We hypothesized that in such tumors, volume measurements alone may not accurately capture changes in actual tumor burden during treatment. We longitudinally evaluated volume changes in both normal-appearing supratentorial white matter and the brain stem lesions in patients treated for diffuse intrinsic pontine glioma to determine to what extent adjuvant systemic therapies may skew the accuracy of tumor response assessments based on volumetric analysis. MATERIALS AND METHODS: The anatomic MR imaging and diffusion tensor imaging data of 26 patients with diffuse intrinsic pontine glioma were retrospectively analyzed. Treatment included conformal radiation therapy in conjunction with vandetanib and dexamethasone. Volumetric and diffusion data were analyzed with time, and differences between time points were evaluated statistically. RESULTS: Normalized brain stem lesion volume decreased during combined treatment (slope = -0.222, P < .001) and increased shortly after completion of radiation therapy (slope = 0.422, P < .001). Supratentorial white matter volume steadily and significantly decreased with time (slope = -0.057, P < .001). CONCLUSIONS: Longitudinal changes in brain stem lesion volume are robust; less pronounced but measurable changes occur in the supratentorial white matter. Volume changes in nonirradiated supratentorial white matter during the disease course reflect the effects of systemic medication on the water homeostasis of normal parenchyma. Our data suggest that adjuvant nontumor-targeted therapies may have a more substantial effect on lesion volume changes than previously thought; hence, an apparent volume decrease in infiltrative tumors receiving combined therapies may lead to overestimation of the actual response and tumor control.
Authors: Andreas J Bartsch; György Homola; Armin Biller; Stephen M Smith; Heinz-Gerd Weijers; Gerhard A Wiesbeck; Mark Jenkinson; Nicola De Stefano; László Solymosi; Martin Bendszus Journal: Brain Date: 2007-01 Impact factor: 13.501
Authors: Katherine E Warren; Tina Y Poussaint; Gilbert Vezina; Darren Hargrave; Roger J Packer; Stewart Goldman; Patrick Y Wen; Ian F Pollack; David Zurakowski; Larry E Kun; Michael D Prados; Stefan Rutkowski; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2013-04-26 Impact factor: 3.167
Authors: Tina Young Poussaint; Mehmet Kocak; Sridhar Vajapeyam; Roger I Packer; Richard L Robertson; Russell Geyer; Daphne Haas-Kogan; Ian F Pollack; Gilbert Vezina; Robert Zimmerman; Soonmee Cha; Zoltan Patay; James M Boyett; Larry E Kun Journal: Neuro Oncol Date: 2011-02-04 Impact factor: 12.300
Authors: Elizabeth R Gerstner; Dan G Duda; Emmanuelle di Tomaso; Peter A Ryg; Jay S Loeffler; A Gregory Sorensen; Percy Ivy; Rakesh K Jain; Tracy T Batchelor Journal: Nat Rev Clin Oncol Date: 2009-04 Impact factor: 66.675